Qiagen N.V. (NYSE: QGEN) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 22.38 | EPS (ttm) | 1.89 | Insider Own | - | Shs Outstand | 206.25M | Perf Week | 2.17% |
| Market Cap | 8.72B | Forward P/E | 16.29 | EPS next Y | 2.60 | Insider Trans | - | Shs Float | 204.78M | Perf Month | 0.74% |
| Enterprise Value | 9.72B | PEG | 0.07 | EPS next Q | - | Inst Own | - | Short Float | 3.87% | Perf Quarter | 26.23% |
| Income | 400.45M | P/S | 4.16 | EPS this Y | 27.33% | Inst Trans | - | Short Ratio | 3.04 | Perf Half Y | -17.43% |
| Sales | 2.10B | P/B | 2.63 | EPS next Y | 7.91% | ROA | 6.96% | Short Interest | 7.93M | Perf YTD | -10.65% |
| Book/sh | - | P/C | 14.23 | EPS next 5Y | 8.32% | ROE | 11.28% | 52W High | 59.83 -26.84% | Perf Year | -10.93% |
| Cash/sh | - | P/FCF | 21.25 | EPS past 3/5Y | -0.16% 44.84% | ROIC | 8.66% | 52W Low | 33.66 30.03% | Perf 3Y | -10.38% |
| Dividend Est. | 0.70 (1.60%) | EV/EBITDA | 12.50 | Sales past 3/5Y | -0.82% 2.25% | Gross Margin | 61.58% | Volatility | 2.39% 2.12% | Perf 5Y | -20.46% |
| Dividend TTM | 2.64 (6.03%) | EV/Sales | 4.63 | EPS Y/Y TTM | 397.37% | Oper. Margin | 24.85% | ATR (14) | 1.04 | Perf 10Y | 72.58% |
| Dividend Ex-Date | Jul 07, 2026 | Quick Ratio | 2.57 | Sales Y/Y TTM | 6.12% | Profit Margin | 19.16% | RSI (14) | 60.97 | Recom | 2.57 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.21 | EPS Q/Q | -1.82% | SMA20 | 1.93% | Beta | 0.62 | Target Price | 43.57 |
| Payout | 13.49% | Debt/Eq | 0.49 | Sales Q/Q | 1.86% | SMA50 | 7.52% | Rel Volume | 1.23 | Prev Close | 42.30 |
| Employees | 5,654 | LT Debt/Eq | 0.44 | Earnings | Nov 03 | SMA200 | -2.03% | Avg Volume | 2.62M | Price | 43.77 |
| IPO Date | Jun 28, 1996 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -0.30% -0.77% | Net Debt/EBITDA | 1.29 | Volume | 3,214,591 | Change | 3.48% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | Stifel Nicolaus | Hold | $36 → $40 |
| Aug-07-26 | Reiterated | Barclays | Equal Weight | $38 → $40 |
| Aug-06-26 | Reiterated | Jefferies | Buy | $46 → $48 |
| Jul-14-26 | Reiterated | Berenberg Bank | $46 | |
| Jun-25-26 | Initiated | Kepler Cheuvreux | Hold | $39 |
| Jun-23-26 | Upgrade | Morgan Stanley | Equal Weight → Overweight | $42 |
| May-18-26 | Reiterated | Stifel Nicolaus | Hold | $50 → $36 |
| Apr-30-26 | Reiterated | Deutsche Bank | Buy | $54 → $43 |
| Apr-29-26 | Reiterated | Robert W. Baird | $53 → $43 | |
| Apr-29-26 | Upgrade | Baird | Neutral → Outperform |
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,099 | 2,090 | 1,978 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 806 | 799 | 1,011 | — | — | — | — | — | — | |
| Gross Profit | 1,292 | 1,291 | 967 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 588 | 584 | 564 | — | — | — | — | — | — | |
| Research and Development | 192 | 188 | 193 | — | — | — | — | — | — | |
| Other Operating Expense | -10 | -1 | 113 | — | — | — | — | — | — | |
| Operating Income | 522 | 520 | 98 | — | — | — | — | — | — | |
| Interest Expense | 37 | 33 | 44 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -28 | 3 | 67 | — | — | — | — | — | — | |
| Net Income Before Taxes | 457 | 490 | 121 | — | — | — | — | — | — | |
| Income Taxes | 55 | 65 | 38 | — | — | — | — | — | — | |
| Consolidated Net Income | 402 | 425 | 84 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 402 | 425 | 84 | — | — | — | — | — | — | |
| Net Income | 402 | 425 | 84 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.89 | 2.04 | 0.39 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.89 | 2.04 | 0.39 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.89 | 2.04 | 0.38 | — | — | — | — | — | — | |
| EBITDA | 778 | 717 | 368 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 23.16 | 23.21 | 114.50 | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.32 | 4.71 | 4.75 | — | — | — | — | — | — | |
| Gross Margin | 61.55 | 61.77 | 48.89 | — | — | — | — | — | — | |
| Operating Margin | 24.87 | 24.88 | 4.95 | — | — | — | — | — | — | |
| Net Margin | 19.15 | 20.33 | 4.25 | — | — | — | — | — | — | |
| Shares Outstanding | 207 | 208 | 216 | — | — | — | — | — | — | |
| Market Capitalization | 9,060 | 9,847 | 9,398 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |